Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.
Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses potential alternate CAR T-cell targets in B-cell malignancies.
Though significant response rates have been demonstrated with CD19-targeting CAR T-cells, investigation into other possible B-cell antigen targets are ongoing, says Park. CD22 is of particular interest, though responses do not appear as durable as those seen with CD19-targeting antigens.
Additionally, dual-targeting CAR T-cell therapy may increase response rates in this field. At the 2019 ASH Annual Meeting, an update from a phase I dose-climbing study (ChiCTR1800018143) showed objective response rates of over 90% was shown with CAR T-cells targeting both CD38 and BCMA in patients with extramedullary multiple myeloma.